Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck
Background There is a need to improve the systemic treatment of advanced adenoid cystic carcinoma (ACC). Response rates to chemotherapy are poor and preliminary investigations of molecularly targeted agents have been disappointing. In this study, we evaluate sorafenib, an oral multikinase inhibitor,...
Gespeichert in:
| Veröffentlicht in: | Head & neck 2015-02, Vol.37 (2), p.182-187 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 187 |
|---|---|
| container_issue | 2 |
| container_start_page | 182 |
| container_title | Head & neck |
| container_volume | 37 |
| creator | Thomson, David J. Silva, Priyamal Denton, Kim Bonington, Suzanne Mak, Soo K. Swindell, Ric Homer, Jarrod Sykes, Andrew J. Lee, Lip W. Yap, Beng K. Slevin, Nicholas J. |
| description | Background
There is a need to improve the systemic treatment of advanced adenoid cystic carcinoma (ACC). Response rates to chemotherapy are poor and preliminary investigations of molecularly targeted agents have been disappointing. In this study, we evaluate sorafenib, an oral multikinase inhibitor, which has an attractive targeting profile for this disease.
Methods
In a single‐arm phase II trial, patients with unresectable locally recurrent and/or metastatic ACC were treated with sorafenib 400 mg bid.
Results
Twenty‐three patients, median age 51 years, were recruited from 2009 to 2011. Median progression‐free survival (PFS) and overall survival (OS) were 11.3 and 19.6 months, respectively. PFS at 6 and 12 months were 69.3% and 46.2%, respectively. Sorafenib was only reasonably well tolerated, and 13 patients (57%) experienced grade 3 toxicity.
Conclusion
Sorafenib showed modest activity in ACC with a 12‐month PFS of 46.2%. Sorafenib 400 mg bid was associated with significant toxicity and, taken together with limited effectiveness, cannot be enthusiastically recommended for further evaluation. © 2014 Wiley Periodicals, Inc. Head Neck 37: 182‐187, 2015 |
| doi_str_mv | 10.1002/hed.23577 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1646582308</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3562343101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5627-5d8fbd5c34b21873ada857de9d6698a43cb77a1dacffde13129fa372d5e20b883</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0E4lFY8APIEisWaf2KnSwRr1ZUgAQIVlgT21EMbQJ2CvTvSWnLjtWMRufembkIHVLSp4SwQeVsn_FUqQ20S0muEsKF2lz0giecKLGD9mJ8JYRwKdg22mGCC5mlahe93FUQHR6NcBs8THBT4tgEKF3tC-xrDPYTauMsjjDxnxDm3cTVjbfYzGPrDTYQjK-bKSykbeVw5cBiqC2unXnbR1slTKI7WNUeery8eDgbJuPbq9HZ6TgxqWQqSW1WFjY1XBSMZoqDhe4663IrZZ6B4KZQCqgFU5bWUU5ZXgJXzKaOkSLLeA8dL33fQ_Mxc7HVr80s1N1KTaWQacY4WVAnS8qEJsbgSv0e_LR7SlOiF0nqLkn9m2THHq0cZ8W0m67JdXQdMFgCX37i5v876eHF-doyWSp8bN33nwLCm5aKq1Q_3Vzp--vx8JlJpgX_AaR8i5c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1646582308</pqid></control><display><type>article</type><title>Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Thomson, David J. ; Silva, Priyamal ; Denton, Kim ; Bonington, Suzanne ; Mak, Soo K. ; Swindell, Ric ; Homer, Jarrod ; Sykes, Andrew J. ; Lee, Lip W. ; Yap, Beng K. ; Slevin, Nicholas J.</creator><creatorcontrib>Thomson, David J. ; Silva, Priyamal ; Denton, Kim ; Bonington, Suzanne ; Mak, Soo K. ; Swindell, Ric ; Homer, Jarrod ; Sykes, Andrew J. ; Lee, Lip W. ; Yap, Beng K. ; Slevin, Nicholas J.</creatorcontrib><description>Background
There is a need to improve the systemic treatment of advanced adenoid cystic carcinoma (ACC). Response rates to chemotherapy are poor and preliminary investigations of molecularly targeted agents have been disappointing. In this study, we evaluate sorafenib, an oral multikinase inhibitor, which has an attractive targeting profile for this disease.
Methods
In a single‐arm phase II trial, patients with unresectable locally recurrent and/or metastatic ACC were treated with sorafenib 400 mg bid.
Results
Twenty‐three patients, median age 51 years, were recruited from 2009 to 2011. Median progression‐free survival (PFS) and overall survival (OS) were 11.3 and 19.6 months, respectively. PFS at 6 and 12 months were 69.3% and 46.2%, respectively. Sorafenib was only reasonably well tolerated, and 13 patients (57%) experienced grade 3 toxicity.
Conclusion
Sorafenib showed modest activity in ACC with a 12‐month PFS of 46.2%. Sorafenib 400 mg bid was associated with significant toxicity and, taken together with limited effectiveness, cannot be enthusiastically recommended for further evaluation. © 2014 Wiley Periodicals, Inc. Head Neck 37: 182‐187, 2015</description><identifier>ISSN: 1043-3074</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.23577</identifier><identifier>PMID: 24346857</identifier><identifier>CODEN: HEANEE</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>adenoid cystic carcinoma ; Adult ; Aged ; Carcinoma, Adenoid Cystic - drug therapy ; Carcinoma, Adenoid Cystic - mortality ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Niacinamide - analogs & derivatives ; Niacinamide - therapeutic use ; Phenylurea Compounds - therapeutic use ; Protein Kinase Inhibitors - therapeutic use ; Salivary Gland Neoplasms - drug therapy ; Salivary Gland Neoplasms - mortality ; sorafenib ; trial</subject><ispartof>Head & neck, 2015-02, Vol.37 (2), p.182-187</ispartof><rights>2014 Wiley Periodicals, Inc.</rights><rights>2015 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5627-5d8fbd5c34b21873ada857de9d6698a43cb77a1dacffde13129fa372d5e20b883</citedby><cites>FETCH-LOGICAL-c5627-5d8fbd5c34b21873ada857de9d6698a43cb77a1dacffde13129fa372d5e20b883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhed.23577$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhed.23577$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24346857$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thomson, David J.</creatorcontrib><creatorcontrib>Silva, Priyamal</creatorcontrib><creatorcontrib>Denton, Kim</creatorcontrib><creatorcontrib>Bonington, Suzanne</creatorcontrib><creatorcontrib>Mak, Soo K.</creatorcontrib><creatorcontrib>Swindell, Ric</creatorcontrib><creatorcontrib>Homer, Jarrod</creatorcontrib><creatorcontrib>Sykes, Andrew J.</creatorcontrib><creatorcontrib>Lee, Lip W.</creatorcontrib><creatorcontrib>Yap, Beng K.</creatorcontrib><creatorcontrib>Slevin, Nicholas J.</creatorcontrib><title>Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
There is a need to improve the systemic treatment of advanced adenoid cystic carcinoma (ACC). Response rates to chemotherapy are poor and preliminary investigations of molecularly targeted agents have been disappointing. In this study, we evaluate sorafenib, an oral multikinase inhibitor, which has an attractive targeting profile for this disease.
Methods
In a single‐arm phase II trial, patients with unresectable locally recurrent and/or metastatic ACC were treated with sorafenib 400 mg bid.
Results
Twenty‐three patients, median age 51 years, were recruited from 2009 to 2011. Median progression‐free survival (PFS) and overall survival (OS) were 11.3 and 19.6 months, respectively. PFS at 6 and 12 months were 69.3% and 46.2%, respectively. Sorafenib was only reasonably well tolerated, and 13 patients (57%) experienced grade 3 toxicity.
Conclusion
Sorafenib showed modest activity in ACC with a 12‐month PFS of 46.2%. Sorafenib 400 mg bid was associated with significant toxicity and, taken together with limited effectiveness, cannot be enthusiastically recommended for further evaluation. © 2014 Wiley Periodicals, Inc. Head Neck 37: 182‐187, 2015</description><subject>adenoid cystic carcinoma</subject><subject>Adult</subject><subject>Aged</subject><subject>Carcinoma, Adenoid Cystic - drug therapy</subject><subject>Carcinoma, Adenoid Cystic - mortality</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Niacinamide - therapeutic use</subject><subject>Phenylurea Compounds - therapeutic use</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Salivary Gland Neoplasms - drug therapy</subject><subject>Salivary Gland Neoplasms - mortality</subject><subject>sorafenib</subject><subject>trial</subject><issn>1043-3074</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0E4lFY8APIEisWaf2KnSwRr1ZUgAQIVlgT21EMbQJ2CvTvSWnLjtWMRufembkIHVLSp4SwQeVsn_FUqQ20S0muEsKF2lz0giecKLGD9mJ8JYRwKdg22mGCC5mlahe93FUQHR6NcBs8THBT4tgEKF3tC-xrDPYTauMsjjDxnxDm3cTVjbfYzGPrDTYQjK-bKSykbeVw5cBiqC2unXnbR1slTKI7WNUeery8eDgbJuPbq9HZ6TgxqWQqSW1WFjY1XBSMZoqDhe4663IrZZ6B4KZQCqgFU5bWUU5ZXgJXzKaOkSLLeA8dL33fQ_Mxc7HVr80s1N1KTaWQacY4WVAnS8qEJsbgSv0e_LR7SlOiF0nqLkn9m2THHq0cZ8W0m67JdXQdMFgCX37i5v876eHF-doyWSp8bN33nwLCm5aKq1Q_3Vzp--vx8JlJpgX_AaR8i5c</recordid><startdate>201502</startdate><enddate>201502</enddate><creator>Thomson, David J.</creator><creator>Silva, Priyamal</creator><creator>Denton, Kim</creator><creator>Bonington, Suzanne</creator><creator>Mak, Soo K.</creator><creator>Swindell, Ric</creator><creator>Homer, Jarrod</creator><creator>Sykes, Andrew J.</creator><creator>Lee, Lip W.</creator><creator>Yap, Beng K.</creator><creator>Slevin, Nicholas J.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope></search><sort><creationdate>201502</creationdate><title>Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck</title><author>Thomson, David J. ; Silva, Priyamal ; Denton, Kim ; Bonington, Suzanne ; Mak, Soo K. ; Swindell, Ric ; Homer, Jarrod ; Sykes, Andrew J. ; Lee, Lip W. ; Yap, Beng K. ; Slevin, Nicholas J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5627-5d8fbd5c34b21873ada857de9d6698a43cb77a1dacffde13129fa372d5e20b883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>adenoid cystic carcinoma</topic><topic>Adult</topic><topic>Aged</topic><topic>Carcinoma, Adenoid Cystic - drug therapy</topic><topic>Carcinoma, Adenoid Cystic - mortality</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Niacinamide - therapeutic use</topic><topic>Phenylurea Compounds - therapeutic use</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Salivary Gland Neoplasms - drug therapy</topic><topic>Salivary Gland Neoplasms - mortality</topic><topic>sorafenib</topic><topic>trial</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thomson, David J.</creatorcontrib><creatorcontrib>Silva, Priyamal</creatorcontrib><creatorcontrib>Denton, Kim</creatorcontrib><creatorcontrib>Bonington, Suzanne</creatorcontrib><creatorcontrib>Mak, Soo K.</creatorcontrib><creatorcontrib>Swindell, Ric</creatorcontrib><creatorcontrib>Homer, Jarrod</creatorcontrib><creatorcontrib>Sykes, Andrew J.</creatorcontrib><creatorcontrib>Lee, Lip W.</creatorcontrib><creatorcontrib>Yap, Beng K.</creatorcontrib><creatorcontrib>Slevin, Nicholas J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thomson, David J.</au><au>Silva, Priyamal</au><au>Denton, Kim</au><au>Bonington, Suzanne</au><au>Mak, Soo K.</au><au>Swindell, Ric</au><au>Homer, Jarrod</au><au>Sykes, Andrew J.</au><au>Lee, Lip W.</au><au>Yap, Beng K.</au><au>Slevin, Nicholas J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2015-02</date><risdate>2015</risdate><volume>37</volume><issue>2</issue><spage>182</spage><epage>187</epage><pages>182-187</pages><issn>1043-3074</issn><eissn>1097-0347</eissn><coden>HEANEE</coden><abstract>Background
There is a need to improve the systemic treatment of advanced adenoid cystic carcinoma (ACC). Response rates to chemotherapy are poor and preliminary investigations of molecularly targeted agents have been disappointing. In this study, we evaluate sorafenib, an oral multikinase inhibitor, which has an attractive targeting profile for this disease.
Methods
In a single‐arm phase II trial, patients with unresectable locally recurrent and/or metastatic ACC were treated with sorafenib 400 mg bid.
Results
Twenty‐three patients, median age 51 years, were recruited from 2009 to 2011. Median progression‐free survival (PFS) and overall survival (OS) were 11.3 and 19.6 months, respectively. PFS at 6 and 12 months were 69.3% and 46.2%, respectively. Sorafenib was only reasonably well tolerated, and 13 patients (57%) experienced grade 3 toxicity.
Conclusion
Sorafenib showed modest activity in ACC with a 12‐month PFS of 46.2%. Sorafenib 400 mg bid was associated with significant toxicity and, taken together with limited effectiveness, cannot be enthusiastically recommended for further evaluation. © 2014 Wiley Periodicals, Inc. Head Neck 37: 182‐187, 2015</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>24346857</pmid><doi>10.1002/hed.23577</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2015-02, Vol.37 (2), p.182-187 |
| issn | 1043-3074 1097-0347 |
| language | eng |
| recordid | cdi_proquest_journals_1646582308 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | adenoid cystic carcinoma Adult Aged Carcinoma, Adenoid Cystic - drug therapy Carcinoma, Adenoid Cystic - mortality Disease Progression Female Humans Male Middle Aged Niacinamide - analogs & derivatives Niacinamide - therapeutic use Phenylurea Compounds - therapeutic use Protein Kinase Inhibitors - therapeutic use Salivary Gland Neoplasms - drug therapy Salivary Gland Neoplasms - mortality sorafenib trial |
| title | Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T01%3A27%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20trial%20of%20sorafenib%20in%20advanced%20salivary%20adenoid%20cystic%20carcinoma%20of%20the%20head%20and%20neck&rft.jtitle=Head%20&%20neck&rft.au=Thomson,%20David%20J.&rft.date=2015-02&rft.volume=37&rft.issue=2&rft.spage=182&rft.epage=187&rft.pages=182-187&rft.issn=1043-3074&rft.eissn=1097-0347&rft.coden=HEANEE&rft_id=info:doi/10.1002/hed.23577&rft_dat=%3Cproquest_cross%3E3562343101%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1646582308&rft_id=info:pmid/24346857&rfr_iscdi=true |